SG11202007117RA - 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof - Google Patents
4-methyldihydropyrimidinone compounds and pharmaceutical use thereofInfo
- Publication number
- SG11202007117RA SG11202007117RA SG11202007117RA SG11202007117RA SG11202007117RA SG 11202007117R A SG11202007117R A SG 11202007117RA SG 11202007117R A SG11202007117R A SG 11202007117RA SG 11202007117R A SG11202007117R A SG 11202007117RA SG 11202007117R A SG11202007117R A SG 11202007117RA
- Authority
- SG
- Singapore
- Prior art keywords
- methyldihydropyrimidinone
- compounds
- pharmaceutical use
- pharmaceutical
- methyldihydropyrimidinone compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018035597 | 2018-02-28 | ||
| PCT/JP2019/007433 WO2019167981A1 (en) | 2018-02-28 | 2019-02-27 | 4-methyldihydropyrimidinone compound and medicinal use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007117RA true SG11202007117RA (en) | 2020-08-28 |
Family
ID=67805061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007117RA SG11202007117RA (en) | 2018-02-28 | 2019-02-27 | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10899717B2 (en) |
| EP (1) | EP3760616A4 (en) |
| JP (1) | JP7282546B2 (en) |
| KR (1) | KR20200126973A (en) |
| CN (1) | CN111741947A (en) |
| AR (1) | AR114270A1 (en) |
| AU (1) | AU2019228915A1 (en) |
| BR (1) | BR112020016785A2 (en) |
| CA (1) | CA3087994A1 (en) |
| CL (1) | CL2020002187A1 (en) |
| CO (1) | CO2020011860A2 (en) |
| IL (1) | IL276323A (en) |
| MX (1) | MX2020008982A (en) |
| PE (1) | PE20210550A1 (en) |
| PH (1) | PH12020551341A1 (en) |
| RU (1) | RU2020131402A (en) |
| SG (1) | SG11202007117RA (en) |
| TW (1) | TW202000650A (en) |
| WO (1) | WO2019167981A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170169A1 (en) | 2016-08-29 | 2019-01-30 | Novartis Ag | Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections |
| WO2021149786A1 (en) | 2020-01-24 | 2021-07-29 | Japan Tobacco Inc. | Methods of treating cancer using dihydropyrimidin-2-one compounds |
| WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4485107A (en) | 1982-11-01 | 1984-11-27 | Janssen Pharmaceutica N.V. | [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones |
| TWI610684B (en) | 2005-12-22 | 2018-01-11 | 海卓勒生物科學公司 | Compounds for modulating trpa1 function |
| US20100010024A1 (en) | 2006-07-01 | 2010-01-14 | Bayer Healthcare Ag | Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension |
| DE102006031314A1 (en) | 2006-07-01 | 2008-01-03 | Bayer Healthcare Aktiengesellschaft | Use of 1,4-diaryl-dihydropyrimidin-2-one derivative for producing a medicament for the treatment and/or prophylaxis of e.g. pulmonary arterial hypertension, chronic-obstructive lung diseases and sleep apnea syndrome |
| WO2009150668A1 (en) | 2008-06-13 | 2009-12-17 | Delhi University | Dihydropyridimidinone compounds for the treatment of cardiovascular diseases and process for preparing the same |
| TWI532728B (en) | 2011-04-28 | 2016-05-11 | 日本煙草產業股份有限公司 | Amide compounds and pharmaceutical uses thereof |
| EP2682389A1 (en) | 2012-07-02 | 2014-01-08 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Dihydropyrimidin-2(1H)-ones and dihydropyrimidin-2(1H)-thiones as inhibitors of sodium iodide symporter |
| JO3215B1 (en) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | Carboxamide or Sulfonamide Substituted Nitrogen-Containing 5-Membered Heterocycles as Modulators for the Orphan Nuclear Receptor RORy |
| WO2014062938A1 (en) | 2012-10-19 | 2014-04-24 | Bristol-Myers Squibb Company | Rory modulators |
| WO2014065413A1 (en) | 2012-10-26 | 2014-05-01 | 日本たばこ産業株式会社 | Triazole-isoxazole compound and medical use thereof |
| CN103113308B (en) | 2013-01-25 | 2014-11-19 | 浙江大学 | Method for preparing dihydropyrimidinone derivative |
| US20160168089A1 (en) | 2014-12-12 | 2016-06-16 | H. Lundbeck A/S | Process for the manufacture of idalopirdine |
| PT3231793T (en) | 2014-12-12 | 2020-05-06 | Japan Tobacco Inc | Dihydropyrimidine-2-one compounds and medicinal uses thereof |
| MX2017007623A (en) | 2014-12-12 | 2018-09-26 | Regenacy Pharmaceuticals Llc | Piperidine derivatives as hdac1/2 inhibitors. |
| EP3229806A1 (en) | 2014-12-12 | 2017-10-18 | Merck Patent GmbH | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor |
-
2019
- 2019-02-27 KR KR1020207024430A patent/KR20200126973A/en not_active Application Discontinuation
- 2019-02-27 AR ARP190100480A patent/AR114270A1/en unknown
- 2019-02-27 EP EP19759983.0A patent/EP3760616A4/en active Pending
- 2019-02-27 WO PCT/JP2019/007433 patent/WO2019167981A1/en unknown
- 2019-02-27 AU AU2019228915A patent/AU2019228915A1/en not_active Abandoned
- 2019-02-27 BR BR112020016785-1A patent/BR112020016785A2/en not_active Application Discontinuation
- 2019-02-27 US US16/287,870 patent/US10899717B2/en active Active
- 2019-02-27 CA CA3087994A patent/CA3087994A1/en active Pending
- 2019-02-27 PE PE2020001289A patent/PE20210550A1/en unknown
- 2019-02-27 SG SG11202007117RA patent/SG11202007117RA/en unknown
- 2019-02-27 RU RU2020131402A patent/RU2020131402A/en unknown
- 2019-02-27 JP JP2019033421A patent/JP7282546B2/en active Active
- 2019-02-27 CN CN201980015795.4A patent/CN111741947A/en active Pending
- 2019-02-27 MX MX2020008982A patent/MX2020008982A/en unknown
- 2019-02-27 TW TW108106799A patent/TW202000650A/en unknown
-
2020
- 2020-07-27 IL IL276323A patent/IL276323A/en unknown
- 2020-08-25 CL CL2020002187A patent/CL2020002187A1/en unknown
- 2020-08-27 PH PH12020551341A patent/PH12020551341A1/en unknown
- 2020-09-24 CO CONC2020/0011860A patent/CO2020011860A2/en unknown
- 2020-12-18 US US17/127,935 patent/US20210363110A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PE20210550A1 (en) | 2021-03-17 |
| CN111741947A (en) | 2020-10-02 |
| EP3760616A1 (en) | 2021-01-06 |
| US20190300488A1 (en) | 2019-10-03 |
| JP2019151623A (en) | 2019-09-12 |
| KR20200126973A (en) | 2020-11-09 |
| EP3760616A4 (en) | 2021-11-03 |
| US20210363110A1 (en) | 2021-11-25 |
| PH12020551341A1 (en) | 2021-06-21 |
| US10899717B2 (en) | 2021-01-26 |
| IL276323A (en) | 2020-09-30 |
| CA3087994A1 (en) | 2019-09-06 |
| CO2020011860A2 (en) | 2021-01-18 |
| CL2020002187A1 (en) | 2020-12-18 |
| WO2019167981A1 (en) | 2019-09-06 |
| MX2020008982A (en) | 2020-09-28 |
| AU2019228915A1 (en) | 2020-07-02 |
| JP7282546B2 (en) | 2023-05-29 |
| TW202000650A (en) | 2020-01-01 |
| AR114270A1 (en) | 2020-08-12 |
| BR112020016785A2 (en) | 2021-02-09 |
| RU2020131402A (en) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2569961B (en) | Pharmaceutical | |
| GB2572126B (en) | Pharmaceutical | |
| IL284835A (en) | Pharmaceutical combination comprising tno155 and ribociclib | |
| GB2572125B (en) | Pharmaceutical | |
| IL290745A (en) | Pyrimidine compound and pharmaceutical use thereof | |
| IL273339A (en) | Griseofulvin compound and pharmaceutical use thereof | |
| IL284514A (en) | Halo-allylamine compounds and use thereof | |
| IL276323A (en) | 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof | |
| GB201715194D0 (en) | Compounds and their therapeutic use | |
| IL280644A (en) | Magnesium-serinate compound and use thereof | |
| IL279483A (en) | Cyanotriazole compounds and uses thereof | |
| IL276311A (en) | Methyllactam ring compound and pharmaceutical use thereof | |
| IL276326A (en) | Saturated-ring-fused dihydropyrimidinone or dihydrotriazinone compounds and pharmaceutical use thereof | |
| IL277502A (en) | Compounds and uses thereof | |
| IL277749A (en) | Pladienolide compounds and their use | |
| IL279877A (en) | Ivosidenib forms and pharmaceutical compositions | |
| SG11202011003TA (en) | Azabenzimidazole compounds and pharmaceutical | |
| EP4069233A4 (en) | Pharmaceutical combination and use thereof | |
| IL282134A (en) | Aromatic compounds and pharmaceutical uses thereof | |
| EP4051270A4 (en) | 4-amino-imidazoquinoline compounds and use thereof | |
| IL292646A (en) | Pharmaceutical combination and use thereof | |
| IL282157A (en) | Compounds and therapeutic uses thereof | |
| EP4082614A4 (en) | Acylsulfamide compound and pharmaceutical use therefor | |
| GB201814520D0 (en) | New pharmaceutical use | |
| HK1254527A1 (en) | Pharmaceutical formulation and use thereof |